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A B S T R A C T
During the last decade, the application of both qualitative and quantitative nucleic acid detection
techniques has had a major impact on diagnostics in clinical virology. Both signal and target
amplification-based systems are currently used routinely in most if not all virology laboratories.
However, commercial assays are only available for a very limited number of targets, and this has
resulted in the development and introduction of assays developed in-house for most viral targets. With
improved and automated nucleic acid sample isolation techniques, as well as real-time detection
methods, a new generation of assays for most clinically important viruses is being developed. These
technological improvements also make it possible to generate results with a very short turnaround time.
As an example of a more individual-patient disease-management concept, we have introduced in our
clinical setting the quantitative detection of Epstein–Barr virus (EBV) in T-cell-depleted allogeneic stem
cell transplant patients. This has enabled us to develop models for pre-emptive anti-B-cell immuno-
therapy for EBV reactivation, and for reducing not only the incidence of EBV lymphoproliferative
disease (EBV-LPD), but the virus-related mortality. It is now also feasible to introduce molecular testing
for those viruses that can easily be detected using classical virological methods, such as culture
techniques or antigen detection. Prospective studies are needed to evaluate the clinical importance of the
additional positive samples detected. It should, however, be clear that a complete exchange of
technology is unlikely to occur, and that complementary methods should stay operational, making
possible the discovery of new viruses. Furthermore, the ability to characterise viruses more easily by
sequencing opens new possibilities for epidemiological studies. There is also an urgent need, with
regard to molecular diagnostic methods, for the introduction and use of standardised materials and
participation in international quality control programmes. Finally, with the introduction of a universal
internal control throughout the whole procedure, the accuracy of the results generated is warranted.
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I N T R O D U C T I O N
Advances have been made during the last
decade making possible the sensitive detection
and characterisation of viral nucleic acids.
Amplification methods, such as PCR and Nucleic
Acid Sequence-Based Amplification (NASBA), in
principal make possible the amplification of any
target of interest. Technological improvements in
sequence detection systems make it possible to
characterise a virus fully, and to determine, for
instance, the subtype, genotype, variant, mutant,
and genotypic resistance patterns. The introduc-
tion of nucleic acid methods into routine diag-
nostics represents a great step forward, with the
introduction of real-time methods to detect
amplified products easily. For an overview, see
Mackay et al. [1] and Niesters [2]. This method is
able to quantify target nucleic acids in a single
sample over a larger dynamic range than most
other quantitative methods, although qualitative
detection is, of course, also possible. Since both
amplification and detection can currently be
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performed automatically, the most labour-inten-
sive and critical step remaining is the efficient
extraction of nucleic acids from different clinical
samples.
A second advance in clinical virology is the
increasing number of antiviral strategies avail-
able, not only for the commercially interesting
viruses HIV, hepatitis B virus (HBV) and hepatitis
C virus (HCV), but also for more ‘general’ viruses
such as Epstein–Barr virus (EBV) and enterovi-
ruses. These new antivirals can, however, only be
used successfully in combination with an optimal
diagnostic strategy and employed in a disease-
management context with an integrated approach
combining diagnostics and treatment.
B O T T L E N E C K S I N M O L E C U L A R
D I A G N O S T I C S
There are still several problems that must be
solved before molecular diagnostics can be rou-
tinely implemented (Table 1). First, it is recog-
nised that commercially standardised assays for
the clinical laboratory are available for only a
limited number of targets (mainly HIV type 1,
HBV and HCV, and, to a limited extent, cyto-
megalovirus (CMV) and human papilloma virus),
and it is unlikely that the number of target viruses
will increase rapidly in the near future. However,
it should be emphasised that there is a large and
growing list of viruses for which the implemen-
tation and use of nucleic acid methods is
advantageous. In Table 2, a tentative list of
‘commercially interesting’ viruses vs. viral targets
with limited commercial interest is given.
The second bottleneck is the easy and repro-
ducible isolation of all nucleic acids (both RNA
and DNA) from several clinical specimens. A
fully automated system with high reliability is
essential for successful implementation of nucleic
acid detection in a day-to-day clinical virological
setting. This will enable the laboratory to generate
results with a short turnaround time, which is
essential for disease management.
The third bottleneck concerns standardisation
and quality control programmes. It has been
Table 1. Bottlenecks in molecular diagnostics
Problem identified Possible solution
1. Quantitative techniques Real-time amplification techniques
2. Internal and external control Well defined universal internal controls (PhHV, PDV)
Quality control programmes
3. Sample preparation still matrix dependent New extraction techniques
4. Hands-on time and turnaround time results Automation
5. Commercially interesting viruses vs.
viruses of no commercial interest
Well characterised home-brew assays
Table 2. Commercially available
assays vs. assays not commercially
available for clinical virology: tar-
gets of interest
Commercially
interesting targets
Important in-house viral
targets to be developed
HIV type 1 HIV type 2
Hepatitis B virus Epstein–Barr virus
Hepatitis C Virus Herpes simplex virus types 1 and 2
Cytomegalovirus Cytomegalovirus
Human papilloma virus Herpesvirus type 6
Varicella zoster virus
Enterovirus
Rhinovirus
Influenza virus
Coronavirus
Respiratory syncitial virus
Human metapneumovirus
Adenovirus
Parvovirus B19
Astrovirus
Calicivirus
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known since the early 1990s that one of the
greatest problems to overcome with molecular
methods is false positivity caused by contamin-
ation, and false negativity associated with the
great differences in sensitivity of, in most cases,
home-brew assays [3–5]. Furthermore, difficulties
in detecting all genotypes of, for example, HIV-1
or HCV, equally, with the same amplification
efficiency, have also been reported [6,7]. Pro-
grammes within Europe have been initiated, and
have, indeed, shown that there is a need to obtain
more standardised material and a need to parti-
cipate in these programmes [8,9]. A successor of
one of these initiatives is called QCMD (Quality
Control for Molecular Diagnostics: http://www.
qcmd.org), endorsed by the European Society for
Clinical Virology (ESCV) and the European Soci-
ety of Clinical Microbiology and Infectious Dis-
eases (ESCMID), which is starting to provide
these quality control programmes for an increas-
ing number of viral targets, whether commer-
cially interesting or not. Besides the need for a
well-defined quality control programme, there is
still a lack of standardisation of quantitative
assays, mainly because standardisation is limited
to a select number of blood-borne viruses, such as
HIV-1, HBV and HCV, for which internationally
accepted (WHO) standards are available [10,11].
These standards are unfortunately only for single
viral genotypes or subtypes, and in most cases
are focused more specifically on blood bank
screening and not on routine virological diagnos-
tics. This is one of the problems that must be
solved if we are to develop assays for the ‘non-
commercially interesting’ viral targets.
U N I V E R S A L I N T E R N A L C O N T R O L S
We have introduced the MagnaPure LC system
(Roche Applied Science, Penzberg, Germany) in
our laboratory as an open extraction system,
initially for the extraction of RNA and DNA
from serum and plasma. Combined with real-
time detection, whether TaqMan technology or
NASBA amplification, this has enabled us to
extract automatically and subsequently detect
both RNA and DNA over a large dynamic range
from a single clinical sample. To monitor this
extraction process for loss or inhibition, we
introduced the use of a universal internal viral
control, which consists of a complete non-human
seal herpesvirus (a DNA virus, PhHV type 1). A
real-time and quantitative TaqMan assay was
developed for this seal herpesvirus, which can be
grown relatively easily in cell culture. The
assumption is that a virus used as a universal
control behaves more similarly in the extraction
procedure to the target virus of interest than
would, for example, a plasmid used as internal
control. A low and fixed amount of this virus
(equal to an amount giving a cycle threshold
value in the real-time assay of c. 30–33, depending
on the lot number used) is added to each clinical
sample (in our case, mostly serum or plasma)
before the extraction procedure starts. This virus
is coextracted and subsequently amplified in a
quantitative manner, while still in a separate tube.
This method monitors the combined effect of
extraction (loss of sample) and amplification
(inhibition), and enables us to be more confident
about the quantitative results generated for the
viral target of interest. In addition, negative
results from clinical samples (or better, no target
detected) can therefore be generated with high
confidence. The data from the internal control are
routinely imported into a spreadsheet program,
with defined thresholds for approval or rejection
of the final results. A typical example is shown in
Fig. 1. Currently, multiplexing of the clinical
sample with the internal control is under devel-
opment. This strategy, furthermore, enables us
to monitor every new approach, equipment or
technique for extraction very rapidly, and enables
us to check whether different lot numbers of
reagents behave identically (or not).
External standards should also be more or less
identical to the samples of interest, with the same
or similar amplification efficiency as the clinical
samples. The matrix in which the external control
is extracted (if it is extracted at all) should be
similar to the samples of interest. This implies that
cloned material as an external control might be
problematic.
Problems with standards and international
standards have already been addressed above,
but the conclusion is that absolute quantification
is very hard to achieve, especially for those viral
targets that would classify as not at present
commercially interesting. Only international col-
laboration, in which diagnostic laboratories
should take the lead, will enable us to tackle
these problems. This does not, of course, exclude
using real-time methods to quantify viral targets,
since this has been shown to give invaluable
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information on how viruses and their hosts
interact.
Q U A N T I F I C A T I O N O F V I R A L
T A R G E T S
With the recent development of real-time methods
and the detection of amplification products gen-
erated by PCR or NASBA methods, the quantifi-
cation of both RNA and DNA in clinical samples
has been made much easier. Also, the availability
of ready-to-go reagents for both (RT)-PCR and
NASBA is a step forward. Numerous examples of
detection and quantification of viral targets have
been published already (for an overview, see
Niesters [2]), and the list is growing rapidly. The
whole process, from isolation to detection, can
now be automated, but, for each target, the
optimal strategy still needs to be established. It
has to be determined which threshold values have
clinical importance, or which detection levels need
to be reached with each assay.
We have been involved in the development of
a pre-emptive strategy to reduce the incidence of
EBV reactivation and the development of EBV-
related lymphomas (known as post-transplant
lymphoproliferative disease (PTLD)) in allogene-
ic T-cell-depleted stem cell transplant patients.
A TaqMan-based assay for the gene encoding the
p143 BNRF protein has been developed and used
to investigate the incidence of EBV reactivation
and the development of EBV-related PTLDs
[12–15]. Moreover, the assay is performed very
frequently (currently five times a week), enabling
us to determine the kinetics of EBV replication in
our patient population. Several conclusions could
be drawn, one of which was that each 10-fold
stepwise increase of EBV DNA measured in
plasma yielded a hazard ratio of 2.9 (95%
confidence interval 1.7–4.8) for developing PTLD
for those patients receiving a T-cell-depleted
graft (p < 0.001). Furthermore, it was shown that
those patients receiving antithymocyte globulin
(ATG) as part of their conditioning regimen
belonged to the population with the highest risk,
and that the T-cell depletion itself was not the
determinant. The problem now was to find at
what viral load one should intervene with a
pre-emptive antiviral strategy, i.e., to identify
precisely those patients at risk. A threshold of
1000 copies ⁄ mL in plasma was chosen as an
indication to start treatment with rituximab, a
monoclonal antibody directed against CD20,
which is the receptor binding site for EBV.
Although this resulted in overtreatment of
patients who experienced EBV reactivation and
most likely would not develop EBV PTLD, a
reduction of EBV PTLD incidence and a complete
abrogation of PTLD mortality at 6 months was
observed [12]. An example of the kinetic pattern
observed with EBV DNA measured in plasma is
shown in Fig. 2. It can be seen that the EBV DNA
viral load can increase very rapidly, making it
necessary to perform the real-time testing on a
regular basis. Monitoring patients at risk, and
follow-up after the initiation of treatment, is thus
frequently necessary.
This strategy of monitoring patients at risk has
also been used successfully for cytomegalovirus
(CMV) [16–18]. Viral load kinetic patterns are
used to identify patients who are more likely to
have recurrence of CMV diseases after the initi-
ation of antiviral therapy, as well as to identify
patients who should be treated.
38
36
34
32
30
28
26
24
0 10 20 30 40 50 60 70 80
Sample number
Ct
 v
al
ue
 P
hH
V1
Fig. 1. Data with the Ct value of the amplification plot of
seal herpes virus type 1 (PhHV-1) added at a fixed
concentration of approximately 5000–8000 copies ⁄mL to
each clinical sample. The results of a single experiment are
shown, imported into a spreadsheet. The virus was
coextracted using the MagnaPure LC isolation station,
and quantified on an ABI7700 sequence detection system,
using TaqMan universal reaction mixture (Applied Bio-
systems, Nieuwerkerk aan de Ijssel, The Netherlands).
Primers and probe sequence were: forward primer
5¢-GGGCGAATCACAGATTGAATC, reverse primer 5¢-
GCGGTTCCAAACGTACCAA, probe (labelled with TET)
5¢-TTTTTATGTGTCCGCCACCATCTGGATC. An amplifi-
cation product of 89 bp within the gB gene is generated.
The average Ct value was 30.68 (average from 2359
samples analysed with this lot number), with an SD of
0.9. Samples in which the Ct value for the internal control
was > 32.5 (average plus 2 SD) had to be repeated (one in
this run, see arrow).
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T H E P R E C I S E D E S C R I P T I O N O F T H E
V I R U S
Once we are able to detect and quantify in
principal any virus of interest, the question
remains whether a more precise characterisation
of the isolated or detected virus is necessary for
patient management. For the blood-borne viruses,
characterisation of the virus is becoming more or
less a routine practice in clinical virology. For
HIV, the genotypic resistance pattern, usually
obtained by sequencing both the reverse tran-
scriptase and protease genes, generates much
information for the determination of optimal
antiretroviral therapy. This is used mostly in
combination with quantitative RNA data. For
HCV, the genotype is important, combined again
with the viral load, for the determination of the
duration of therapy using interferon and ribavirin
[19]. Also, for HBV, there are accumulating data
indicating a relationship between genotype and
the success of antiviral treatment [20].
Sequencing is, in principle, the ultimate meth-
od of characterisation. A disadvantage, however,
is that, during antiviral treatment, a mixture of
both wild-type and variant virus exists. It has
been observed that sequencing is not very
suitable for the detection of minor populations
of variant viruses [21]. Other methods, such as
reverse hybridisation [22–24] or restriction frag-
ment length polymorphism analysis [25,26],
might be more suitable, but it should be clear
that they can only be successful if the sequence
changes in a specific gene are known. Again, viral
load measurements can be very helpful when
searching for new variants during antiviral treat-
ment, as has been recently described for the
discovery of a new HBV variant resistant to
lamivudine [26].
As sequencing technology is implemented in
more laboratory settings, the question is whether
it should be used for the characterisation of viral
targets for which serotyping is currently used. It
has already been shown that sequencing can be
successful for the characterisation of enterovirus-
es and rhinoviruses, with results comparable to
those obtained with serotyping [27,28].
I S T H E R E S T I L L A P L A C E F O R V I R U S
C U L T U R E ?
The implementation of molecular methods has
resulted not only in an improvement in diagnos-
tics for a number of viruses, using the quantitative
detection of nucleic acids and the monitoring of
antiviral therapy, especially for HIV-1, HBV and
HCV, but also in the development of an ampli-
fication assay for almost every human virus,
including those viruses that can be cultured
relatively easily, e.g., the herpesviruses HSV types
1 and 2 [29]. These new molecular methods have
several advantages, especially in those settings in
which routine virus culture is not available.
However, it should also be noted that improved
sensitivity over virus culture is observed in
almost all instances. The introduction of molecu-
lar diagnostics into routine clinical diagnostic
virology is proceeding rapidly, and it will ulti-
mately replace or reduce the use of virus culture
techniques. The implementation of automated
extraction and detection methods, combined with
an extensive quality control programme, should
ultimately convince both clinicians and virologists
that molecular diagnostics is important in clinical
virology. A critical remark often made is that not
all positive results will have clinical significance,
but this will be countered by good clinical and
epidemiological information, combined with
quantitative information on the virus(es) present.
However, the ability to exclude viral infections
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Fig. 2. Pre-emptive (PE) anti-B-cell immunotherapy for
EBV. To monitor patients at risk for EBV PTLD, EBV DNA
load was measured on a regular basis. At a level of
1000 copies ⁄ mL, the patients were recalled to the hospital,
and PE therapy with rituximab (anti-CD20 therapy) was
initiated. Monitoring was performed five times a week,
until the EBV DNA level was twice below the limit of
detection of the assay (50 copies ⁄ mL). If the signal did not
decrease rapidly (or an increase was observed), a second
infusion of rituximab or an infusion of donor lymphocytes
(DLI) was given (see data represented by a thick line). The
initiation of PE therapy is represented as day 0. Each line
represents an individual patient.
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has the advantage that unnecessary therapeutic
options are not implemented, such as the wrong
antivirals or antibiotics, which inevitably will
reduce the overall costs of patient care. However,
financial figures are needed to prove this. Thus,
with improved accuracy and sensitivity, com-
bined with a more rapid turnaround time, these
molecular techniques are important for patient
care, providing information to guide the best
therapeutic options.
There is, of course, still a need for virus culture,
as otherwise we will be unable to identify new
viruses circulating, such as the recently described
human metapneumovirus [30], but it is clear that
a major transition from virus culture to molecular
diagnostics is at hand.
C O N C L U S I O N S
The availability of open technologies to isolate and
amplify nucleic acids makes possible not only the
routine isolation of nucleic acids from an increas-
ing range of clinical materials, but also, because of
the use of real-time detection systems, the whole
process of semi-automatic, quantitative detection
of viral RNA and DNA targets. Furthermore, the
risk of contamination is minimised, and the
turnaround time for the generation of results,
with minimal handling by personnel, whether
positive or negative, is becoming shorter. Results
can be generated easily within a working day, and
it is expected that, in the near future, this will be
reduced to hours.
Molecular techniques are becoming part of
routine clinical virology, and the home-brew
assays are maturing, since standardised reagents
and improved quality control programmes are
enhancing laboratory performance. Most import-
antly, these standardised reagents are getting
cheaper, making the discussion concerning high
costs obsolete.
One of the greatest advantages, however, is the
ability to detect more positive target sequences in
clinical samples. This will not only give us
insights into the relationship between virus and
host, but, importantly, will also allow patients at
risk to be treated more specifically. Molecular
testing has been successful in those areas in which
conventional virological techniques did not exist
or could be improved. Currently, molecular test-
ing is also available for those targets for which
conventional technology is available. Logistics
within the laboratory, price of assays, and clinical
benefit will be the new criteria that will make
these technological improvements a fundamental
part of the new era in a diagnostic setting.
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